Product Description
Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Mechanisms of Action: GM-CSF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Germany, Netherlands
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Roivant Sciences presented P2 Sarcoidosis, Pulmonary results on 2024-12-03 for Namilumab
Highest Development Phases
Phase 2: Sarcoidosis, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| KIN-1902-2001 | P2 |
Completed |
Sarcoidosis, Pulmonary |
2025-03-31 |
2025-05-02 |
Treatments |
|
| Resolve-Lung | P2 |
Active, not recruiting |
Sarcoidosis, Pulmonary |
2024-11-15 |